Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma

Belantamab mafodotin (belamaf), an antibody-drug conjugate approved for the treatment of relapsed and refractory multiple myeloma (RRMM), is an anti B-cell maturation antigen (BCMA) agent. DREAMM-1, a first in-human trial of belamaf, reported several ocular toxicities requiring dose adjustments, dos...

Descripción completa

Detalles Bibliográficos
Autores principales: Wahab, Ahsan, Rafae, Abdul, Mushtaq, Kamran, Masood, Adeel, Ehsan, Hamid, Khakwani, Maria, Khan, Aqsa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8148346/
https://www.ncbi.nlm.nih.gov/pubmed/34046363
http://dx.doi.org/10.3389/fonc.2021.678634

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8148346/
https://www.ncbi.nlm.nih.gov/pubmed/34046363
http://dx.doi.org/10.3389/fonc.2021.678634

Ejemplares similares